TNFRSF17 and plasma cell myeloma: In 2024, an mRNA-engineered anti-BCMA CAR-T candidate, Descartes-15, entered Phase I evaluation for relapsed/refractory multiple myeloma (RRMM) (NCT06304636) [321,322], which achieved durable responses without lymphodepleting conditioning.